Checkmate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) - A phase 2 study Meeting Abstract
| Authors: | Younes, A.; Santoro, A.; Zinzani, P. L.; Timmerman, J.; Ansell, S. M.; Armand, P.; Fanale, M. A.; Ratanatharathorn, V.; Kuruvilla, J.; Cohen, J. B.; Collins, G. P.; Savage, K. J.; Trněný, M.; Kato, K.; Farsaci, B.; Parker, S. M.; Rodig, S. J.; Shipp, M. A.; Engert, A. |
| Abstract Title: | Checkmate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) - A phase 2 study |
| Meeting Title: | 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 34 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2016 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2016-05-20 |
| Start Page: | 403s |
| Language: | English |
| ACCESSION: | WOS:000404711505048 |
| DOI: | 10.1200/JCO.2016.34.15_suppl.7535 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 7535 -- Source: Wos |
